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Summary
Background Globally, cervical cancer is the fourth leading cause of cancer-related death among women. Poor uptake 
of screening services contributes to the high mortality. We aimed to examine screening frequency, predictors of 
screening results, and patterns of sensitisation strategies by age group in a large, programmatic cohort.
Methods We did a cohort study including 11 government health facilities in Lusaka, Zambia, in which we reviewed 
routine programmatic data collected through the Cervical Cancer Prevention Program in Zambia (CCPPZ). 
Participants who underwent cervical cancer screening in one of the participating study sites were considered for 
study inclusion if they had a screening result. Follow-up was accomplished per national guidelines. We did descriptive 
analyses and mixed-effects logistic regression for cervical cancer screening results allowing random effects at the 
individual and clinic level.
Findings Between Jan 1, 2010, and July 31, 2019, we included 183 165 women with 204 225 results for visual inspection 
with acetic acid and digital cervicography (VIAC) in the analysis. Of all those screened, 21 326 (10·4%) were VIAC-
positive, of whom 16 244 (76·2%) received treatment. Of 204 225 screenings, 92 838 (45·5%) were in women who 
were HIV-negative, 76 607 (37·5%) were in women who were HIV-positive, and 34 780 (17·0%) had an unknown HIV 
status. Screening frequency increased 65·7% between 2010 and 2019 with most appointments being first-time 
screenings (n=158 940 [77·8%]). Women with HIV were more likely to test VIAC-positive than women who were 
HIV-negative (adjusted odds ratio 3·60, 95% CI 2·14–6·08). Younger women (≤29 years) with HIV had the highest 
predictive probability (18·6%, 95% CI 14·2–22·9) of screening positive.
Interpretation CCPPZ has effectively increased women’s engagement in screening since its inception in 2006. 
Customised sensitisation strategies relevant to different age groups could increase uptake and adherence to screening. 
The high proportion of screen positivity in women younger than 20 years with HIV requires further consideration. 
Our data are not able to discern if women with HIV have earlier disease onset or whether this difference reflects 
misclassification of disease in an age group with a higher sexually transmitted infection prevalence. These data 
inform scale-up efforts required to achieve WHO elimination targets.
Funding US President’s Emergency Plan for AIDS Relief.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
Globally, approximately 527 000 new cases of cervical 
cancer and 265 000 deaths are recorded every year.1 The 
burden of cervical cancer is projected to increase, 
and is compounded by the HIV epidemic.1,2 Although 
primary and secondary screening strategies have greatly 
reduced cervical cancer in high-income countries, this 
approach has yet to reach low-income and middle-
income countries.3 Success in incidence reduction is 
reliant upon adequate coverage and adherence to 
screening services.4,5 The WHO global strategy towards 
the elimination of cervical cancer as a public health 
problem requires that 90% of girls are vaccinated with 
the human papillomavirus (HPV) vaccine by the age of 
15 years, 70% of women are screened with a high 
performance test by 35 years with a repeat screening 
by 45 years, and 90% of women identified with both 
pre-cancerous and invasive cervical cancer receive 
treatment.6 However, targets pertaining to women with 
HIV have yet to be distinguished from the general 
population. Previous research has established women 
with HIV to be at an earlier and more persistent risk of 
cervical cancer than their counterparts who do not have 
HIV. However, sufficient data to define a minimum set 
of age-specific screening targets in this high-risk group 
have yet to be presented.7–10
Screening coverage needs to reach 70% of eligible 
women to result in a decrease in the incidence of cervical 
cancer.11 Zambia’s cervical cancer prevention programme 
has been very effective in terms of increasing women’s 
engagement in screening since its inception in 2006. It 
has used various strategies for increasing screening 
coverage, including educational interventions, physician 
reminders, or incentive programmes, as well as strategies 
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targeting the community, such as mass media campaigns, 
outreach to community members, and leveraging com-
munity health workers.12–16 Evaluation of effective referral 
mechanisms for cervical cancer screening by age and 
HIV status and cervical cancer screening retention or 
follow-up have not been fully described in sub-Saharan 
Africa, to our knowledge.
The Cervical Cancer Prevention Program in Zambia 
(CCPPZ) is the largest nurse-led public sector programme 
of its kind in sub-Saharan Africa, training nurses to 
provide eligible women with free, personalised cervical 
cancer screening through visual inspection with acetic 
acid and digital cervicography (VIAC) as an adjunct for 
quality assurance.17–19 In Zambia, women aged 30–59 years 
are screened every 5 years while women with HIV aged 
25–59 years are screened at an interval of 3 years if they 
have had a previously negative screening result.20 Women 
outside of these target groups are also considered for 
screening on the basis of individual risk assessment. 
Women who have a positive result are offered cryotherapy 
or thermal ablation on the same day as screening if the 
lesion covers less than 75% of the cervix, can be completely 
covered by the cryotherapy probe, is fully visible on the 
ectocervix, and is not suspicious for cancer according to 
clinical judgment. This approach reflects the so-called see 
and treat model endorsed by WHO and adapted by the 
Ministry of Health Zambia.18,19,21 If the lesion does not 
meet the criteria for immediate treatment, patients are 
referred for histological evaluation with either large loop 
electrical excision of the transformation zone or punch 
biopsy, punch biopsy if the lesion is clinically suspicious 
for invasion. If treatment for pre-cancer was indicated, 
follow-up after 1 year is recommended in both the general 
population and women with HIV.
Since 2006, CCPPZ led by the Ministry of Health 
Zambia, and in close partnership with the Centre for 
Infectious Disease Research in Zambia (CIDRZ), has 
implemented cervical cancer screening using both a 
standalone and integrated model in government-led 
clinics.2 The CCPPZ is the first large-scale, public sector 
cervical cancer prevention intervention effort in Zambia 
and remains one of the largest programmes of its type 
Research in context
Evidence before this study
We searched MEDLINE and PubMed without language 
restrictions and last updated the search on Jan 19, 2021, using 
the search terms “cervical cancer screening” and “Zambia”, 
which yielded 55 results. We found that the last publication 
evaluating cervical cancer screening in Zambia (published in 
2015) reports on the Cervical Cancer Prevention Program in 
Zambia (CCPPZ) from 2006 to 2013. We also searched “cervical 
cancer screening”, “sensitization”, and “HIV”, which yielded 
118 results. We reviewed these publications, national and 
international guidelines for cervical cancer screening, and other 
relevant studies known to our research group. Few longitudinal 
studies have been done in sub-Saharan Africa to assess cervical 
cancer screening outcomes, especially in the context of the 
current guidelines. Furthermore, to date there are no studies to 
our knowledge that have evaluated cervical cancer screening 
sensitisation strategies. We believe that the findings of our 
study are novel and could help drive tailored approaches for 
improved cervical cancer screening programmes.
Added value of this study
The present study is a novel assessment of cervical cancer 
screening uptake, sensitisation, and outcomes by age and 
HIV status in Zambia from 2010 to 2019. We evaluated a 
large, programmatic cervical cancer screening cohort of 
183 165 women at 11 health facilities in Lusaka, Zambia. 
This evaluation has not been done previously using national 
cervical cancer screening data from Zambia. We highlight some 
key findings. Firstly, the results of this study show that the 
predictive probability of screening positive was highest among 
women who were HIV-positive aged 20–29 years, followed 
very closely by those younger than 20 years. Secondly, we 
found that the possibility of receiving same-day treatment for 
pre-cancerous lesions was significantly higher for women who 
were HIV-negative than for women who were HIV-positive. 
This finding is particularly important in the Zambian context, 
where providing same-day treatment is favoured to enable a 
strong link between screening and treatment. Thirdly, we 
found that follow-up intervals are currently similar for both 
women who are HIV positive or negative. Lastly, we found that 
customised sensitisation strategies relevant to different age 
groups might increase the uptake to cervical cancer screening 
in Zambia.
Implications of all the available evidence
Cervical cancer is largely preventable but remains one of the 
leading causes of cancer-related death for women living in 
sub-Saharan Africa. Scale-up of screening services is required to 
achieve the WHO targets (ie, 90% of girls vaccinated by the age 
of 15 years, 70% of women screened at 35 years and 45 years, 
and 90% of women identified with both pre-cancerous and 
invasive cervical cancer receive treatment) in Zambia and 
regionally. These findings could assist policy makers and 
stakeholders with strategies to enable evidence-based 
expansion of cervical cancer screening services. These data 
support consideration of customised sensitisation strategies 
by demographic and clinical characteristics to increase uptake 
of screening for cervical cancer. Furthermore, regular 
programme evaluations might provide useful information for 
the prioritisation of investments and support health system 
strengthening. As we transition to human papillomavirus 
testing strategies, ongoing monitoring including indicators for 
long-term outcomes for women, could help to further 
strengthen the programme.
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in sub-Saharan Africa. Initially implemented as an 
intervention targeting women with HIV, it is now 
part of routine health service delivery for all Zambian 
women, irrespective of HIV status. We aimed to explore 
screening frequency successes, examine predictors of 
cervical cancer screening results and treatment outcomes, 
and describe sensitisation strategies—defined as reported 
screening referral methods (ie, peer educator, health 
facility)—among those accessing cervical cancer 
screening services according to age group and HIV status 
using 9 years of CCPPZ data.
Methods
Study design and participants
We did a cohort study in which we analysed data from 
the CCPPZ of women accessing cervical cancer 
screening through routinely offered screening services 
at all 11 government health facilities that provided 
screening services in Lusaka, Zambia. These facilities 
were Bauleni, Chawama, Chelstone, Chilenje, George, 
Kalingalinga, Kanyama, Matero Reference Hospital, 
Mtendere, Ngombe, and University Teaching Hospital. 
All study activity was done as part of monitoring and 
evaluation by the CIDRZ for the President’s Emergency 
Plan for AIDS Relief funded Capacity Building and 
Strengthening Implementation of HIV Combination 
Prevention and Treatment Services (ACHIEVE) Project 
and the Ministry of Health. The ACHIEVE Project 
supports the HIV care cascade and cervical cancer 
screening services throughout Zambia.All women who 
underwent cervical cancer screening as part of routine 
care and had a valid result in the 11 government health 
facilities were included in the analysis cohort. Follow-up 
for women who underwent cervical cancer screening was 
determined based on their previous results per national 
guidelines. This study was approved by the University 
of Zambia Biomedical Research Ethics Committee 
(number 005-11-17) and the institutional review boards at 
Washington University (St Louis, MO, USA), without 
requiring patient consent given the use of de-identified, 
routinely collected programmatic data (number 
201911143).
Procedures
All data were collected and entered on site by a trained 
nurse into an electronic database including socio-
demographic data, method of cervical cancer screening 
referral, HIV status, cervical VIAC results, treatment 
referral, type, and post-screening clinical plan. Data 
queries were adjudicated from disparate electronic 







Median 34 (28–42) 33 (27–40) <0·0001
<20 2562 (1·4%) 247 (1·2%) <0·0001
20–29 47 111 (25·8%) 5555 (26·0%) ··
30–39 53 738 (29·4%) 6877 (32·2%) ··
40–49 33 169 (18·1%) 3255 (15·3%) ··
≥50 17 962 (9·8%) 1327 (6·2%) ··
Unknown 28 357 (15·5%) 4065 (19·1%) ··
HIV status
Negative 86 007 (47·0%) 6831 (32·0%) <0·0001
Positive 65 244 (35·7%) 11 363 (53·3%) ··
Unknown 31 648 (17·3%) 3132 (14·7%) ··
Visit type
Enrolment 142 404 (77·9%) 16 536 (77·5%) 0·29
Follow-up 40 495 (22·1%) 4790 (22·5%) ··
Referral
Community 6213 (3·4%) 319 (1·5%) <0·0001
Family and friends 3126 (1·7%) 290 (1·4%) ··
Health facility 28 144 (15·4%) 2320 (10·9%) ··
Media 3371 (1·8%) 237 (1·1%) ··
Peer educator 21 243 (11·6%) 1869 (8·8%) ··
Unknown 120 802 (66·0%) 16 291 (76·4%) ··
Year screened
2010 12 660 (6·9%) 2692 (12·6%) <0·0001
2011 13 008 (7·1%) 2569 (12·0%) ··
2012 17 494 (9·6%) 2950 (13·8%) ··
2013 17 263 (9·4%) 2354 (11·0%) ··
2014 16 047 (8·8%) 1789 (8·4%) ··
2015 14 198 (7·8%) 1123 (5·3%) ··
2016 13 266 (7·3%) 1071 (5·0%) ··
2017 22 313 (12·2%) 1928 (9·0%) ··
2018 22 955 (12·6%) 1843 (8·6%) ··
2019 23 493 (12·8%) 1946 (9·1%) ··
Unknown 10 202 (5·6%) 1061 (5·0%) ··






(Continued from previous column)
Health facility
Bauleni 4048 (2·2%) 468 (2·2%) <0·0001
Chawama 18 845 (10·3%) 1382 (6·5%) ··
Chelstone 16 537 (9·0%) 1968 (9·2%) ··
Chilenje 7411 (4·1%) 332 (1·6%) ··
George 23 069 (12·6%) 2263 (10·6%) ··
Kalingalinga 11 253 (6·2%) 1637 (7·7%) ··
Kanyama 28 002 (15·3%) 2970 (13·9%) ··
Matero Reference 
Hospital
18 439 (10·1%) 2264 (10·6%) ··
Mtendere 22 002 (12·0%) 2287 (10·7%) ··
Ngombe 6030 (3·3%) 873 (4·1%) ··
University 
Teaching Hospital
27 263 (14·9%) 4882 (22·9%) ··
Data are n (%) or median (IQR), unless specified. VIAC=visual inspection with 
acetic acid and digital cervicography.  
Table 1: Population characteristics among those screened 
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maintained by CIDRZ-supported staff, and de-identified 
at CIDRZ headquarters in Lusaka, Zambia. To account 
for screening heterogeneity across facilities, we allowed 
for random effects at the facility level. We evaluated the 
predictors of VIAC positivity by HIV status and age.
Statistical analysis
We used mixed-effects logistic regression to evaluate 
screening results allowing for a random effect at the 
facility and individual level. All available covariates 
were included in the multivariate model per a priori 
identification of confounders via directed acyclic graph. 
We analysed the interaction between age and HIV status 
in the final regression model. Multiple imputation 
methods were considered for cases in which missing 
data were less than 15% and covariate values met 
assumptions to be considered missing at random. 
Longitudinal analysis was limited to within-facility 
observations (ie, across facility repeat testing and 
treatment was not possible). Predictive probability 
estimates were based on results of the mixed-effects 
regression model. All analyses were done using R, 
version 3.6.1, and Stata SE 15.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Between Jan 1, 2010, and July 31, 2019, data for 
183 165 women with 204 225 VIAC screening results 
were collected. The median age of women was 34 years 
(IQR 28–42). Of the 204 225 screening results, 
21 326 (10·4%) were VIAC-positive. Among those 
screening positive, 7165 (33·6%) completed cryotherapy 
at the screening visit. Of the 204 225 observations, 
76 607 (37·5%) were in women who were HIV-positive, 
92 838 (45·5%) were in women who were HIV-negative, 
and 34 780 (17·0%) had an unknown HIV status (table 1). 
At least one follow-up screening result was available for 
14 677 (8·0%) women and referral information was 
recorded for 67 132 (32·9%) screenings.
Table 1 shows the demographic characteristics of the 
screened population. Most women attending screening 
were aged 30–39 years (n=60 615 [29·7%]) followed 
by 20–29 years (n=52 666 [25·8%]), and 40–49 years 
(n=36 424 [17·8%]). Overall, the number of women 
screened per year increased from 15 352 in 2010 to 25 439 
in July, 2019 (partial year), corresponding to an increased 
annual uptake of 65·7% (figure 1A). A small proportion 
of women attending screening were aged 50 years and 
older (n=19 289; figure 1B). Women younger than 
20 years comprised the smallest proportion of screening 
patients (n=2809 [1·4%]). Patient-reported method of 
uptake was answered by 67 132 (32·8%) women. Most 
women reported that they were referred by a health 
facility (n=30 464 [14·9%]), 23 112 (11·3%) reported that 
the method of referral was through a peer educator, 
6532 (3·2%) via the community (ie, community health 
workers, community leaders, and churches), 3608 (1·8%) 
by the media, and 3416 (1·7%) by family and friends 
(table 1). There were significant differences in population 
characteristics across VIAC results in all covariates, 
except visit type (table 1).
University Teaching Hospital reported the largest 
proportion of screening (n=32 145 [15·7%]) across all 
11 health facilities, followed by Kanyama (n=30 972 
[15·2%]), George (n=25 332 [12·4%], and Mtendere clinics 
(n=24 289 [11·9%]; figure 1A). We observed heterogeneity 
Figure 1: Screening population characteristics
















































































































www.thelancet.com/lancetgh   Vol 9   June 2021 e836
across facilities by age, proportion VIAC-positive, and 
HIV status among those screened (appendix p 1).
The highest probability of screening positivity was 
identified among women with HIV aged 20–29 years 
followed closely by the youngest age group (<20 years; 
figure 2D). A significant difference was seen in probability 
of being screen positive across HIV status for all age 
groups except the oldest (≥50 years). Although there were 
fewer women screened in the younger than 20 years age 
group, this age group was associated with the highest 
probability of screening VIAC-positive. In all age groups, 
women with HIV had a greater risk of screen positivity 
than women who were HIV-negative (adjusted odds ratio 
[OR] 3·60, 95% CI 2·14–6·08; p<0·0001; table 2). Table 2 
shows that referrals from family and friends were 
significantly more likely to screen positive (adjusted OR 1·73, 
95% CI 1·13–1·67; p=0·012), compared with com munity 
referrals. No difference was observed in the risk of 
screening positivity at a follow-up visit compared with 
enrolment (adjusted OR 0·96, 95% CI 0·80–1·15; p=0·66; 
table 2).
Follow-up screening spacing differed depending on 
screening test result upon enrolment (figure 1B). The 
mean number of visits per participant was 1·11. Those 
who had a positive screening result at enrolment 
returned for follow-up screening more readily (mean 
follow-up interval 1·16 years, IQR 1·00–2·42) than those 
who had a negative VIAC result at enrolment (2·56 years, 
IQR 1·50–3·20; Mann-Whitney p<0·0001). Follow-up 
VIAC screening results were negative for 76·3% of those 
previously VIAC-positive with a specified treatment on 
record (14·3%). A known HIV status upon enrolment 
was not significantly associated with a median follow-
up interval among women who were HIV-positive 
(2·25 years, IQR 1·08–3·09) or HIV-negative (2·18 years, 
1·12–3·13).
Method of uptake for most women was by community 
health workers or other health facilities (eg, antiretroviral 
therapy clinics, sexual health clinics, and maternal 
child health clinics). Disaggregating by age group, we 
found that in the younger age groups, peer educator 
referrals resulted in the most number of enrolments 
resulting in a significant difference compared with the 
older age groups, for which health facility and community 
referrals resulted in the highest uptake (χ² p<0·0001; 
figure 1C).
Time to return to follow-up did not differ by HIV 
status; however, it was significantly different by previous 
VIAC result at 1, 2, and 3 years of follow-up time. The 
survival function for a previous VIAC-positive result 
compared with a previous VIAC-negative result was 
0·70 (95% CI 0·69–0·71) and 0·51 (0·49–0·54) at 1 year 
of follow-up, 0·49 (0·48–0·50) and 0·17 (0·15–0·19) 
at 2 year follow-up, and 0·30 (0·28–0·31) and 0·09 
(0·07–0·11) at 3 year follow-up.
Treatment with cryotherapy at screening visit was 
recorded for 33·6% of those who were VIAC-positive. 
The rate of cryotherapy was higher among the younger 
age group (59·1%) than the 50 years and older age 
group (11·7%). Additionally, those who were HIV-
negative (45·0%) were more likely to receive cryotherapy 
on the same day as screening than women who were 
HIV-positive (25·1; figure 2B).
Most recorded screenings were initial or enrolment 
visits (n=158 940 [77·8%]), with the remaining 45 285 being 
follow-up visits, of which 24 225 individuals enrolled 
before our review period. A large proportion of the 
enrolment screenings were among women with HIV 
(n=76 607 [37·5%]), which is likely to be related to the 
initial CCPPZ directive to target women with HIV first 
and then expand to include the HIV-negative population. 
We did not observe a significant difference in VIAC 
screening result by visit type (ie, enrolment visit or follow-
up visit; OR 0·97, 95% CI 0·84–1·12).
Over the 9-year period reviewed, screening enrolment 
increased from 18 671 to 25 562 women and more than 
200 000 screenings were done in Lusaka, Zambia.
Discussion
Our study of a large, programmatic cohort found that 
women with HIV aged younger than 30 years had the 
Figure 2: Measures of VIAC screening result by HIV status and age
(A) Distribution of HIV-positive and screen positive results by age. (B) Scatter plot of same-day cryotherapy 
appointment by age and HIV status (n=21 326). (C) Screening positivity given HIV status. (D) Probability of screening 
positivity according to age group and HIV status. VIAC=visual inspection with acetic acid and digital cervicography. 
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highest predictive probability of being VIAC-positive 
compared with their older counterparts. Although previous 
research reported that those on antiretroviral therapy have 
a chronic, deficient immunity, which predisposes them to 
cervical cancer between the ages of 30–40 years, we found 
that younger women with HIV aged 20–29 years had the 
highest predictive probability of being screen positive 
(18·6%, 95% CI 14·2–22·9) followed very closely by those 
younger than 20 years (18·4%, 9·6–27·3).22–24 These 
findings build on previous work identifying those younger 
than 37·5 years to be at higher odds (adjusted OR 1·6, 
95% CI 0·9–2·9) for cervical lesions compared with those 
aged 37·5 years and older.9 With our large sample size, we 
were able to show that the highest odds for screening 
positive are among women aged 20–29 years (adjusted 
OR 1·81, 95% CI 1·32–2·47).
In general, women in the 30–39 years age group 
had the highest proportion of positive screening 
results (11·3%) among those with age recorded; 
however, there was a significant difference by HIV 
status with women who were HIV-positive aged 
30–39 years with more than twice the predictive 
probability of having a positive result. Women who were 
HIV-positive and younger than 20 years had more than 
three times the predictive probability (18·4, 95% CI 
9·56–27·32) for being positive compared with women 
who were HIV-negative in the same age group 
(predictive probability 5·5%, 95% CI 3·2–7·8). The 
increased prevalence of cervical lesions in sub-Saharan 
Africa, especially among young women, might be 
associated with early age of marriage or first sexual 
intercourse, multiple sexual partners, and low HPV 
vaccination awareness, accessibility, or availability.8
Overall, we observed a significantly increased odds 
(OR 3·60, 95% CI 2·14–6·08) for being screen positive 
among women with HIV compared with women who 
were HIV-negative, which supports previous findings 
in the region including South Africa, Uganda, and 
Zimbabwe.9,25–30 Mechanisms for increased odds for 
being VIAC-positive among women with HIV might be 
explained, in part, by the effect of HIV on the immune 
system, which could lead to chronic HPV infection and 
increased susceptibility to new lesions.31,32
We identified a significant difference in the self-
reported source of referral for cervical cancer screening 
by age group, most notably in the youngest (<20 years) 
age group compared with those aged 20 years and older. 
Young women reported referral predominantly from 
peer educators, whereas older women more often 
reported referral by their health facility or community. 
This finding suggests that different strategies should be 
considered to target and increase uptake among different 
groups of the population. The data also indicate that the 
programme successfully engaged women to attend a 
single-visit service. However, because women with HIV 
are at greatest risk of a persistent pre-cancerous lesion, 
recurrent disease, and ultimately invasive cervical cancer, 
adherence to follow-up recommendations should be 
reinforced.33 More resources to increase re-screening 
could be considered in the next stage of scale-up. In the 
general population, seeking twice per lifetime screening 
(at 35 years and 45 years) could also be considered as an 
interim step.6 Additionally, high prevalence of screening 
positivity among adolescent girls coupled with the 
preferred mode of sensitisation could be leveraged to 
improve targeted outreach and reduce cervical cancer 
risk among young women. These results highlight the 
importance of targeting women with HIV at first sexual 
intercourse and consolidate the case of implementation 
of a nationwide HPV vaccination programme.
Given that our data are dependent upon provider 
proficiency, there could be some misalignment between 
screening test positivity and neoplastic lesions, as 
visually, cervicitis and other benign cervical lesions 
could be mistaken for pre-cancerous disease (sharing 
Crude Adjusted
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Age, years
<20 1·45 (1·08–1·78) 0·011 1·31 (0·95–1·82) 0·098
20–29 1·84 (1·33–2·18) <0·0001 1·81 (1·32–2·47) <0·0001
30–39 2·00 (1·57–2·14) <0·0001 1·69 (1·33–1·97) <0·0001
40–49 1·43 (1·18–1·61) <0·0001 1·22 (0·98–1·51) 0·077
≥50 1 (ref) ·· 1 (ref) ··
HIV status
Negative 1 (ref) ·· 1 (ref) ··
Positive 2·19 (2·12–2·26) <0·0001 3·60 (2·14–6·08) <0·0001
Unknown 1·25 (1·19–1·30) <00001 1·37 (1·15–1·64) <0·0001
Referral
Community 1 (ref) ·· 1 (ref) ··
Media 1·38 (0·82–2·34) 0·23 1·11 (0·70–1·77) 0·65
Family and friends 1·98 (1·27–3·08) 0·0030 1·73 (1·13–1·67) 0·012
Health facility 1·77 (1·23–2·54) 0·0020 1·07 (0·69–1·67) 0·76
Peer educator 1·73 (0·90–3·32) 0·10 1·16 (0·72–1·88) 0·54
Unknown 2·67 (1·78–4·00) <0·0001 1·20 (0·79–1·84) 0·39
Visit type
Enrolment 1 (ref) ·· 1 (ref) ··
Follow-up 0·83 (0·71–0·97) 0·020 0·96 (0·80–1·15) 0·66
Year screened
2010 2·42 (1·90–3·10) <0·0001 4·34 (2·92–6·46) <0·0001
2011 2·22 (1·75–2·82) <0·0001 4·16 (2·77–6·25) <0·0001
2012 1·87 (1·49–2·34) <0·0001 3·31 (2·20–4·98) <0·0001
2013 1·52 (1·11–2·08) 0·0090 2·74 (1·56–4·81) <0·0001
2014 1·22 (1·12–1·33) <0·0001 1·84 (1·65–2·05) <0·0001
2015 0·88 (0·70–1·10) 0·25 1·39 (1·12–1·73) 0·0030
2016 0·95 (0·81–1·10) 0·48 1·37 (1·14–1·65) <0·0001
2017 1·00 (0·83–1·21) 0·10 1·36 (1·12–1·64) 0·0020
2018 0·93 (0·76–1·14) 0·49 1·28 (0·99–1·20) 0·062
2019 1 (ref) ·· 1 (ref) ··
Data are odds ratio (95% CI). VIAC=visual inspection with acetic acid and digital cervicography. 
Table 2: Crude and adjusted predictors for screening VIAC-positive
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many of the same physical character istics).34 Thus, it is 
possible that women with HIV are more likely to be 
misclassified for increased cervical cancer risk as they 
might be less likely to clear infections because of their 
immune status.35,36 These findings could also indicate 
that women with HIV have earlier disease progression, 
meaning that these women should be engaged in 
screening at a younger age. Efforts to change screening 
methods to HPV screening are underway and could 
help to prevent misclassification of disease in women 
with HIV. It is noted that in the absence of histo-
pathology, we cannot comment on true disease and 
missed cases, which is a weakness of VIAC-based 
screening programmes. Without systematic histopatho-
logical evaluation, screening and treatment efficacy 
also remains difficult to evaluate. Current guidelines 
recommend that women with HIV should be referred 
for cervical cancer screening after their first sexual 
interaction, irrespective of age. However, this guideline 
is rarely implemented.
A greater proportion of women who are HIV-negative 
received same-day cryotherapy than their HIV-positive 
counterparts of the same age. This discrepancy could be 
related to the tendency for women who are HIV-positive 
to have more extensive lesions, which are ineligible for 
treatment with local ablative methods.37,38
This study has several limitations. First, we assessed 
screening outcomes only. The test accuracy of the VIAC 
method to identify pre-cancerous lesions (cervical 
intraepithelial neoplasia grade 2 or worse) is an 
inherent weakness.8,22,38,39 The sensitivity of VIAC in 
Africa is reported to range greatly, with a sensitivity 
from 25% (95% CI 7–59) to 82% (66–95) and specificity 
from 74% (64–82) to 83% (77–87).38,40 As a consequence, 
we cannot vouch for accuracy or effect of this service. 
Without histopathology, we are unable to comment on 
true disease, missed cases, overtreatment, or persistent 
disease. These efficacy measures are important out-
comes of screening programmes, which also require 
con sideration. Self-reported methods of uptake were 
also presented. One of the issues with self-reported 
questions is a response bias, and this factor should 
be considered in relation to women’s responses to 
method of uptake. Lastly, complications associated with 
electronic records across several platforms could have 
resulted in some loss of data; however, we do not have 
reason to believe that these data were not missing at 
random across our measured covariates. These issues 
are also likely to be improved in the coming years with 
the initiation of a national electronic medical records 
system for cervical cancer called Smart-Cerv and the 
established population-based cancer registry for Lusaka 
District.
This study is a timely contribution that supports the 
WHO’s guidance on eliminating cervical cancer.6 We 
present health system data that show predominantly a 
single-visit approach to screening and treatment and 
highlights that where HIV prevalence is high, the target 
screening ages stated in the guidance (35 years 
and 45 years) might need to be earlier. We found the 
highest predictive probability and adjusted odds for 
VIAC-positive results among younger women aged 
20–29 years who were HIV-positive. We note the 
limitations of VIAC in this assessment and argue the 
need for other methods of screening and diagnosis in 
Zambia and other low-income and middle-income 
country settings.
Zambia’s cervical cancer prevention programme 
has been very effective in scaling up cervical cancer 
screenings in all ten provinces of Zambia and 
increasing women’s engagement in services. More than 
800 000 women have now been screened since the 
inception of the programme in 2006. This large cervical 
cancer screening programme review provides a strong 
real-world evidence base to inform the scale-up required 
to achieve cervical cancer elimination targets of 
70% women screened by 2030 in Zambia and beyond.6 
These data suggest that customised sensitisation 
strategies relevant to different age groups might 
increase the uptake and adherence to cervical cancer 
screening in Zambia. We found that among women 
with HIV, the highest adjusted odds and predictive 
probability occurred in the 20–29 year age group, 
suggesting particular attention to be paid to this 
younger, high risk group. Overall, our data inform scale-
up efforts required to achieve WHO elimination targets 
of 70% of women screened, and 90% treated by 2030 
over and above the aim for 90% of girls to be vaccinated 
by the age of 15 years by 2030.
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Figure 3: Kaplan-Meier estimates for time to follow-up screening
Shading indicates 95% CI. VIAC=visual inspection with acetic acid and digital cervicography.
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